Pfizer and BioNTech said on Monday that three doses of their COVID-19 vaccine produced a strong immune response in children under the age of five in their clinical trial. Pfizer and BioNTech said they found that the vaccine was up …
Pfizer and BioNech announced on Thursday that a third booster vaccine increases immune defenses against COVID-19 in children ages 5 to 11, particularly against the Omicron variant. Pfizer and BioNTech said that blood serum analysis of a few pediatric participants …
Drugmakers Sanofi and GSK announced on Feb. 23 that they are planning to seek approval from regulators for their COVID-19 vaccine. The companies said data from clinical trials showed that their vaccine works either as a primary vaccine or as …
New Zealand medicines regulator Medsafe on Feb. 4 granted provisional approval for the Novavax COVID-19 vaccine for people aged 18 years and over. The provisional approval does not mean that New Zealand has committed to use Novavax as it is …
The United Kingdom on Feb. 3 approved the Novavax COVID-19 vaccine for people over the age of 18. The Medicines and Healthcare products Regulatory Agency (MHRA) granted the vaccine regulatory approval, following a “rigorous review of safety, quality, and effectiveness,” …
Pfizer and BioNTech on Feb. 1 has requested the United States Food and Drug Administration (FDA) to expand the use of its COVID-19 vaccine to children aged six months to four years. The companies said they applied for the emergency …
Novavax has formally submitted a request for the United States Food and Drug Administration (FDA) to grant emergency use authorization for its COVID-19 vaccine for adults. The vaccine, taken in two doses 21 days apart, demonstrated an overall efficacy of …
Moderna has started a clinical trial to test its COVID-19 vaccine booster shot specifically targeted against the highly contagious Omicron variant, the company announced on Jan. 26. Moderna said that its Phase 2 study, which is its first trial using …
Pfizer is aiming to have a COVID-19 vaccine that specifically targets the Omicron variant to be ready in March, the chief executive officer (CEO) said on Jan. 10. Pfizer CEO Albert Bourla told CNBC’s “Squawk Box” that his company has …
The European Commission has approved on Nov. 10 a deal with French vaccine company Valneva to supply up to 60 million doses of its COVID-19 vaccine candidate over the next two years. Under the deal, nearly 27 million doses of …
